
ADiTx Therapeutics ADTX
ADiTx Therapeutics Operating Cash Flow | ADTX
Annual Operating Cash Flow ADiTx Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.7 M | -16.8 M | -19.2 M | -22.4 M | -22.3 M | -7.22 M | -464 K | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -464 K | -25.7 M | -16.3 M |
Quarterly Operating Cash Flow ADiTx Therapeutics
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.58 M | -9.25 M | -2.34 M | -2.38 M | -11.7 M | - | -2.36 M | -2.29 M | -5.96 M | -3.94 M | -8.03 M | -3.28 M | -3.95 M | -6.72 M | -7.82 M | -2.65 M | -5.2 M | -8.69 M | -4.53 M | -5.01 M | -4.05 M | -3.15 M | -4.07 M | -406 K | -251 K | - | -415 K | -309 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -251 K | -11.7 M | -4.36 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Praxis Precision Medicines
PRAX
|
-249 M | $ 300.01 | -3.5 % | $ 6.75 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
-56.3 M | $ 3.22 | -1.08 % | $ 248 M | ||
|
ProQR Therapeutics N.V.
PRQR
|
-52.8 M | $ 1.02 | -2.38 % | $ 107 M | ||
|
Ocular Therapeutix
OCUL
|
-205 M | $ 5.57 | -5.03 % | $ 1.04 B | ||
|
Sana Biotechnology
SANA
|
-144 M | $ 1.58 | -9.2 % | $ 400 M | ||
|
Outlook Therapeutics
OTLK
|
-51.8 M | $ 0.39 | -2.79 % | $ 13.6 M | ||
|
uniQure N.V.
QURE
|
-178 M | $ 19.32 | -4.5 % | $ 1.11 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
-466 M | $ 16.46 | -4.41 % | $ 1.62 B | ||
|
Rafael Holdings
RFL
|
-30 M | $ 0.94 | 5.89 % | $ 48.3 M | ||
|
REGENXBIO
RGNX
|
-124 M | $ 7.16 | -0.35 % | $ 369 M | ||
|
Rigel Pharmaceuticals
RIGL
|
75.7 M | $ 40.05 | -2.78 % | $ 720 M | ||
|
Celsion Corporation
CLSN
|
-13.9 M | - | -6.63 % | $ 13.9 M | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Tenax Therapeutics
TENX
|
-35.8 M | $ 1.27 | -8.27 % | $ 49.8 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
3.63 B | $ 514.68 | -1.15 % | $ 132 B | ||
|
Genfit SA
GNFT
|
15.5 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-12.9 M | - | -13.47 % | $ 169 M | ||
|
SELLAS Life Sciences Group
SLS
|
-28.4 M | $ 13.67 | -8.01 % | $ 1.49 B | ||
|
CureVac N.V.
CVAC
|
102 M | - | - | $ 867 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B | ||
|
Rezolute
RZLT
|
-64.6 M | $ 3.92 | -6.69 % | $ 407 M | ||
|
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-1.53 M | $ 0.63 | -7.05 % | $ 67.2 M | ||
|
MorphoSys AG
MOR
|
-296 M | - | 2.43 % | $ 254 M | ||
|
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-55.1 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M | ||
|
Seer
SEER
|
-44.4 M | $ 1.34 | -3.25 % | $ 74.5 M | ||
|
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | ||
|
Summit Therapeutics
SMMT
|
-323 M | $ 9.94 | -6.01 % | $ 7.43 B | ||
|
Shattuck Labs
STTK
|
-39.9 M | $ 4.49 | -1.43 % | $ 312 M | ||
|
Silence Therapeutics plc
SLN
|
-39.4 M | $ 19.81 | 0.08 % | $ 2.81 B | ||
|
Soligenix
SNGX
|
-10.3 M | $ 0.22 | -8.25 % | $ 1.14 M | ||
|
Sanofi
SNY
|
10.8 B | $ 46.51 | 0.97 % | $ 56.8 B | ||
|
Spruce Biosciences
SPRB
|
-33.3 M | $ 38.02 | -6.11 % | $ 29.1 M | ||
|
Spero Therapeutics
SPRO
|
-12.6 M | $ 0.74 | -10.95 % | $ 41.5 M | ||
|
Sarepta Therapeutics
SRPT
|
-205 M | $ 13.34 | -5.86 % | $ 1.34 B | ||
|
Savara
SVRA
|
-101 M | $ 4.28 | -17.95 % | $ 952 M | ||
|
Sutro Biopharma
STRO
|
-177 M | $ 8.6 | -1.38 % | $ 73.1 M | ||
|
Tarsus Pharmaceuticals
TARS
|
-12.5 M | $ 72.94 | -6.09 % | $ 3.05 B | ||
|
Supernus Pharmaceuticals
SUPN
|
47.3 M | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
-24.8 M | $ 63.39 | -2.3 % | $ 9.15 B | ||
|
Viridian Therapeutics
VRDN
|
-276 M | $ 29.91 | -4.87 % | $ 3.05 B | ||
|
Trevi Therapeutics
TRVI
|
-42.1 M | $ 13.35 | -2.73 % | $ 1.8 B |